US EditionMedical Affairs: Closing the gap between access and adoption - Breakthrough T1D
Summary by breakthrought1d.org
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Medical Affairs: Closing the gap between access and adoption - Breakthrough T1D
When Tzield was approved by the United States Food and Drug Administration (FDA), the type 1 diabetes (T1D) community had real cause to celebrate: The first disease-modifying therapy for T1D had cleared one of the last major hurdles to becoming available. Disease-modifying therapies Also "DMTs" for short, these therapies prevent, slow, halt, or reverse T1D progression. But once Tzield was on the market and covered by health insu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
